News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Basilea Pharmaceutica (BSLN.SW) Announces Discontinuation of Sale of Ceftobiprole by Janssen-Cilag AG, a Johnson & Johnson (JNJ) Company, In Switzerland


9/9/2010 7:03:45 AM

BASEL, SWITZERLAND--(Marketwire - September 09, 2010) -

Basilea Pharmaceutica AG / Discontinuation of sale of ceftobiprole in Switzerland processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that Janssen-Cilag AG, a Johnson & Johnson company, will be discontinuing sale of ceftobiprole (Zevtera™) for the treatment of complicated skin and soft tissue infections (cSSTI) in Switzerland.

Janssen-Cilag AG, the holder of the Marketing Authorization in Switzerland, has requested Swissmedic to withdraw the marketing authorization of Zevtera™ and will discontinue sale of Zevtera™ as of September 17, 2010. This action is being taken based on the unfavorable assessments of the marketing authorization applications for ceftobiprole in the United States and the European Union.

Physicians are advised to allow all patients on Zevtera™ to complete their course of therapy and not to initiate treatment of new patients. Zevtera™ was authorized in Switzerland in November 2008 for the treatment of cSSTI. There have been no safety observations that would be in conflict with the approved label of Zevtera™.

The decision to discontinue sale of the product in the Swiss market does not preclude the submission of a new application for marketing authorization in the future.

Corresponding requests for the withdrawal of Marketing Authorizations are being submitted to health authorities by a respective Janssen-Cilag company holding the Marketing Authorization in Russia, Ukraine and Azerbaijan, the remaining countries in which ceftobiprole is currently approved.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SWISS: BSLN). Its fully integrated research and development operations are currently focused on antibiotics, antifungals and oncology drugs, as well as on the development of dermatology drugs, targeting the medical challenge of resistance and non-response to current treatment options in the hospital and specialty care setting.

Basilea is currently marketing Toctino® (alitretinoin), the only approved treatment for severe chronic hand eczema unresponsive to potent topical corticosteroids, in Denmark, France, Germany, Switzerland and the United Kingdom and has appointed distributors for Toctino® in other selected European markets, Canada and Mexico. Furthermore, a phase III clinical program on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S. The company has entered into a global partnership with Astellas Pharma Inc. for its phase III compound isavuconazole, a potential best-in-class azole antifungal, for the treatment of life-threatening invasive fungal infections. Full rights to ceftobiprole for the treatment of potentially life-threatening resistant bacterial infections, are being transferred back to Basilea from Cilag GmbH International, a Johnson & Johnson company.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

+-----------------------------+--------------------------------+
| Media Relations             | Investor Relations             |
+-----------------------------+--------------------------------+
| Adesh Kaul                  | Barbara Zink, Ph.D., MBA       |
| Head Public Relations &     | Head Corporate Development     |
| Corporate Communications    |                                |
| +41 61 606 1460             | +41 61 606 1233                |
| media_relations@basilea.com | investor_relations@basilea.com |
+-----------------------------+--------------------------------+

This press release can be downloaded from www.basilea.com



[HUG#1443360]





Ceftobiprole Discontinuation SWI: http://hugin.info/134390/R/1443360/387537.pdf




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE




Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES